JP2022035920A5 - - Google Patents

Info

Publication number

JP2022035920A5

JP2022035920A5 JP2020187268A JP2020187268A JP2022035920A5 JP 2022035920 A5 JP2022035920 A5 JP 2022035920A5 JP 2020187268 A JP2020187268 A JP 2020187268A JP 2020187268 A JP2020187268 A JP 2020187268A JP 2022035920 A5 JP2022035920 A5 JP 2022035920A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

combination

patient

protein

administered

Prior art date

2020-11-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 102000007347 Apyrase Human genes 0.000 claims description 66
• 108010007730 Apyrase Proteins 0.000 claims description 66
• 229960002528 ticagrelor Drugs 0.000 claims description 17
• OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 claims description 17
• 230000000302 ischemic effect Effects 0.000 claims description 15
• 238000012986 modification Methods 0.000 claims description 8
• 230000004048 modification Effects 0.000 claims description 8
• 102100029725 Ectonucleoside triphosphate diphosphohydrolase 3 Human genes 0.000 claims description 6
• 101001012432 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 3 Proteins 0.000 claims description 6
• 150000001413 amino acids Chemical group 0.000 claims description 6
• 230000000694 effects Effects 0.000 claims description 6
• 238000006467 substitution reaction Methods 0.000 claims description 6
• 238000002560 therapeutic procedure Methods 0.000 claims description 5
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
• 229960001138 acetylsalicylic acid Drugs 0.000 claims description 4
• 238000013146 percutaneous coronary intervention Methods 0.000 claims description 4
• 230000010410 reperfusion Effects 0.000 claims description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
• 108091006112 ATPases Proteins 0.000 claims description 2
• 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
• 102000057290 Adenosine Triphosphatases Human genes 0.000 claims description 2
• 239000004475 Arginine Substances 0.000 claims description 2
• 239000004471 Glycine Substances 0.000 claims description 2
• 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
• 208000006117 ST-elevation myocardial infarction Diseases 0.000 claims description 2
• 206010000891 acute myocardial infarction Diseases 0.000 claims description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
• 230000003247 decreasing effect Effects 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 22
• 239000003814 drug Substances 0.000 claims 7
• 229940079593 drug Drugs 0.000 claims 1
• 239000000890 drug combination Substances 0.000 claims 1
• 239000003112 inhibitor Substances 0.000 description 39
• 238000000034 method Methods 0.000 description 27
• 239000002172 P2Y12 inhibitor Substances 0.000 description 3
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
• 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 2
• 239000005465 B01AC22 - Prasugrel Substances 0.000 description 2
• 229960001080 cangrelor Drugs 0.000 description 2
• PAEBIVWUMLRPSK-IDTAVKCVSA-N cangrelor Chemical compound C1=NC=2C(NCCSC)=NC(SCCC(F)(F)F)=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O PAEBIVWUMLRPSK-IDTAVKCVSA-N 0.000 description 2
• 229960003009 clopidogrel Drugs 0.000 description 2
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 229960004197 prasugrel Drugs 0.000 description 2
• DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 2
• 229960005001 ticlopidine Drugs 0.000 description 2
• PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 2
• 208000032109 Transient ischaemic attack Diseases 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 238000013151 thrombectomy Methods 0.000 description 1
• 230000002537 thrombolytic effect Effects 0.000 description 1
• 201000010875 transient cerebral ischemia Diseases 0.000 description 1